Dash Bio
Summary active Updated Aug 4, 2026This profile is AI-generated. If you spot an error, please help us fix it by sharing a URL to the correct information.
Founders
About
Dash Bio is a Waltham, Massachusetts-based bioanalysis company that operates a 24,000-square-foot GLP-compliant, fully automated laboratory serving pharmaceutical and biotechnology drug developers 123. The company pairs laboratory robotics with a proprietary custom laboratory operating system and productized assay workflows spanning ELISA, MSD, qPCR, droplet digital PCR (ddPCR), and LC-MS, delivering preclinical results in days rather than months with transparent pricing and digital traceability 13. Dash Bio reports serving more than 30 customers within nine months of commercial launch, including four of the world’s 15 largest pharmaceutical companies 3. The founding team previously architected digital and automation infrastructure at Moderna 3. Prior to the Series A, Dash Bio raised $11M in July 2025, bringing total funding to $17.5M before this round 4.
Funding History
| Date | Round | Amount | Lead | Co-investors |
|---|---|---|---|---|
| 2026-08-03 | Series A | $30M | Oak HC/FT | Freestyle Capital, Swift Ventures 123 |
| 2025-07 | Seed extension | $11M | — | — 4 |
What Investors Say
“In less than two years, the Dash team has built a GLP-compliant, fully automated bioanalysis platform that the industry’s largest drug developers are already adopting.” — Andy Smith, Partner at Oak HC/FT 1
What Founders Say
“The pace of drug development should be set by the science, not by queues and legacy process.” — Dave Johnson, Co-Founder and CEO of Dash Bio 1
Sources
-
“Dash Bio Raises $30M Series A to Accelerate Drug Development Timelines,” BioSpace, August 3, 2026. Accessed August 4, 2026. https://www.biospace.com/press-releases/dash-bio-raises-30m-series-a-to-accelerate-drug-development-timelines↩↩↩↩↩
-
“Dash Bio raises $30M Series A led by Oak HC/FT,” Endpoints News, August 3, 2026. Accessed August 4, 2026. https://endpoints.news/dash-bio-raises-30m-series-a-led-by-oak-hc-ft/↩↩
-
“Dash Bio Raises $30 Million Series A To Expand Automated Bioanalysis Platform,” Pulse 2.0, August 4, 2026. Accessed August 4, 2026. https://pulse2.com/dash-bio-raises-30-million-series-a-to-expand-automated-bioanalysis-platform/↩↩↩↩↩
-
“Dash Bio Secures $11M to Accelerate a New Era in Bioanalysis — Bringing Total Funding to $17.5M,” PR Newswire, July 2025. Accessed August 4, 2026. https://www.prnewswire.com/news-releases/dash-bio-secures-11m-to-accelerate-a-new-era-in-bioanalysis–bringing-total-funding-to-17-5m-302511151.html↩↩